Estados financieros detallados de Acrivon Therapeutics, Inc. Common Stock (ACRV): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $1.70, ACRV presenta beneficios negativos (P/E no significativo) y un ROE del -70.14%. La capitalización bursátil es de $73M.
Cuenta de Resultados (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $13000 | 0 | 0 | $536000 | $1.0M | $1.4M |
| Beneficio Bruto | -$13000 | 0 | 0 | -$536000 | -$1.0M | -$1.4M |
| I+D | $1.9M | $13.7M | $23.9M | $45.5M | $64.0M | $60.0M |
| Generales y Administrativos | $1.3M | $2.5M | $8.7M | $21.2M | $25.2M | $24.1M |
| Gastos Operativos | $3.2M | $16.2M | $32.7M | $66.7M | $88.2M | $82.8M |
| Beneficio Operativo | -$3.2M | -$16.2M | -$32.7M | -$67.2M | -$89.2M | -$84.1M |
| EBITDA | -$5.3M | -$16.2M | -$30.8M | -$59.9M | -$79.5M | -$76.5M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$5.3M | -$16.2M | -$31.2M | -$60.4M | -$80.6M | -$77.9M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$5.3M | -$16.2M | -$31.2M | -$60.4M | -$80.6M | -$77.9M |
| BPA | $-0.41 | $-1.26 | $-1.42 | $-2.74 | $-2.10 | $-2.02 |
| BPA Diluido | $-0.41 | $-1.26 | $-1.42 | $-2.74 | $-2.10 | $-2.02 |
| Acciones en Circulación (Diluidas) | $12.9M | $12.9M | $21.9M | $22.1M | $38.3M | $38.5M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | $911000 | -$383000 | 0 |
| Beneficio Operativo | -$19.7M | -$20.1M | -$19.9M | -$18.7M |
| EBITDA | -$17.9M | -$24.8M | -$18.7M | -$17.6M |
| Beneficio Neto | -$18.2M | -$19.0M | -$19.0M | -$18.0M |
| BPA | $-0.47 | $-0.49 | $-0.49 | $-0.43 |
| BPA Diluido | $-0.47 | $-0.49 | $-0.49 | $-0.43 |
Balance (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $1.6M | $99.6M | $29.5M | $36.0M | $39.8M | $41.5M |
| Inversiones a Corto | 0 | 0 | $98.2M | $91.4M | $139.7M | $77.1M |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $1.7M | $100.4M | $132.1M | $129.7M | $181.6M | $120.4M |
| Inmovilizado Material | $59000 | $5.8M | $6.9M | $7.9M | $8.0M | $7.4M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $2.2M | $106.6M | $181.2M | $138.3M | $196.6M | $129.7M |
| Cuentas por Pagar | $136000 | $964000 | $904000 | $5.0M | $758000 | $2.3M |
| Deuda a Corto | $58000 | 0 | 0 | 0 | $1.1M | 0 |
| Pasivos Corrientes | $613000 | $2.9M | $6.5M | $13.3M | $17.2M | $15.7M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $10.6M | $130.4M | $10.8M | $17.1M | $19.8M | $17.2M |
| Reservas | -$8.6M | -$24.9M | -$56.0M | -$116.4M | -$197.0M | -$274.9M |
| Patrimonio Neto | -$8.4M | -$23.8M | $170.5M | $121.2M | $176.8M | $112.5M |
| Deuda Total | $58000 | $5.6M | $5.0M | $4.6M | $3.6M | $2.7M |
| Deuda Neta | -$1.5M | -$94.0M | -$122.8M | -$122.8M | -$175.8M | -$115.9M |
| Capital Circulante | $1.1M | $97.5M | $125.6M | $116.4M | $164.4M | $104.8M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $35.4M | $41.5M | $34.1M | $41.4M |
| Activos Totales | $145.3M | $129.7M | $107.8M | $99.1M |
| Pasivos Totales | $16.7M | $17.2M | $12.3M | $12.4M |
| Patrimonio Neto | $128.6M | $112.5M | $95.5M | $86.7M |
| Deuda Total | $3.0M | $2.7M | $2.4M | $2.1M |
Flujo de Caja (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$5.3M | -$16.2M | -$31.2M | -$60.4M | -$80.6M | -$77.9M |
| Amortizaciones | $13000 | $37000 | $364000 | $536000 | $1.0M | $919000 |
| Compensación en Acciones | $3000 | $497000 | $2.2M | $11.6M | $14.3M | $14.7M |
| Cambio en Capital Circulante | $317000 | $328000 | -$1.5M | $8.1M | $2.4M | -$2.4M |
| Flujo de Caja Operativo | -$2.8M | -$14.0M | -$30.1M | -$42.6M | -$65.7M | -$63.7M |
| Inversiones (CapEx) | -$15000 | -$238000 | -$2.2M | -$1.3M | -$2.8M | -$1.7M |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$2.8M | -$14.2M | -$32.3M | -$43.9M | -$68.4M | -$65.3M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$12.3M | -$15.2M | -$20.5M | -$14.9M |
| Inversiones (CapEx) | -$899000 | -$219000 | -$14000 | -$87000 |
| Flujo de Caja Libre | -$13.2M | -$15.5M | -$20.6M | -$14.9M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $3.9M | $3.1M | $2.2M | $2.2M |
Crecimiento y Márgenes (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | -206.1% | -91.9% | -93.8% | -33.4% | +3.3% |
| Crecimiento BPA (anual) | | -207.3% | -12.7% | -93.0% | +23.4% | +3.8% |
| Cambio en Acciones (anual) | | +0.0% | +69.8% | +0.7% | +73.5% | +0.6% |
| Crecimiento FCF (anual) | | -404.6% | -127.0% | -36.1% | -55.8% | +4.5% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.22 | $-1.10 | $-1.47 | $-1.99 | $-1.79 | $-1.70 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $12.9M | $12.9M | $21.9M | $22.1M | $38.3M | $38.5M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -70.14% |
| Rentabilidad sobre capital invertido | -88.28% |
| Rentabilidad sobre activos | -74.91% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.02 |
| Ratio corriente | 7.99 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -0.90 |
Ratios Clave (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -40.59 | -13.21 | -8.11 | -1.80 | -2.87 | -1.19 |
| P/VC | -25.53 | -9.02 | 1.48 | 0.90 | 1.30 | 0.82 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |